Potential drug ‐drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the national covid cohort collaborative (N3C)

Conclusions and RelevanceOne in six of individuals receiving nirmatrelvir/ritonavir were at risk of a potential moderate or severe DDI, underscoring the importance of clinical and pharmacy systems to mitigate such risks.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - August 9, 2023 Category: Drugs & Pharmacology Authors: Xuya Xiao, Hemalkumar B. Mehta, Jill Curran, Brian T. Garibaldi, G. Caleb Alexander, National Covid Cohort Collaborative (N3C) Consortium Tags: RESEARCH ARTICLE Source Type: research